CoChat

A critical role for Lyn in acute myeloid leukemia

Dos Santos, Cédric, Demur, Cécile, Bardet, Valérie, Prade-Houdellier, Nais, Payrastre, Bernard, Récher, Christian · 2008 · Blood
Cited by 141

The DOI matches its Crossref record.

Abstract

Receptor or nonreceptor tyrosine kinases (TKs) are known to play an important role in leukemogenesis. Here we studied the level of protein tyrosine phosphorylations in a series of fresh AML samples and evaluated the effect of TK inhibitors. Compared with normal hematopoietic progenitors, a high level of tyrosine phosphorylation was detected in most acute myeloid leukemia (AML) samples. The Src family kinases (SFKs) appeared constitutively activated in most cases, including in the CD34+CD38−CD123+ compartment as revealed by the level of phosphorylated tyrosine 416. Lyn was the major SFK family member expressed in an active form in AML cells where it was abnormally distributed throughout the plasma membrane and the cytosol as opposed to normal hematopoietic progenitors. The SFK inhibitor, PP2, strongly reduced the global level of tyrosine phosphorylations, inhibited cell proliferation, and induced apoptosis in patient samples without affecting normal granulomonocytic colony forming units. Moreover, silencing Lyn expression by small interfering RNA in primary AML cells strongly inhibited proliferation. Interestingly, a link between Lyn and the mTOR pathway was observed as PP2 and a Lyn knockdown both affected the phosphorylation of mTOR targets without inhibiting Akt phosphorylation. Lyn should be considered as a novel pharmacologic target for AML therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2007-04-082099

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 43

  1. Bonnet, 1997, Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell., Nat Med, 3, 730, 10.1038/nm0797-730 · DOI · Paper page
  2. Passegue, 2003, Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?, Proc Natl Acad Sci U S A, 100, 11842, 10.1073/pnas.2034201100 · DOI · Paper page
  3. Tallman, 2005, Drug therapy for acute myeloid leukemia., Blood, 106, 1154, 10.1182/blood-2005-01-0178 · DOI · Paper page
  4. Kelly, 2002, Genetics of myeloid leukemias., Annu Rev Genomics Hum Genet, 3, 179, 10.1146/annurev.genom.3.032802.115046 · DOI · Paper page
  5. Milella, 2001, Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia., J Clin Invest, 108, 851, 10.1172/JCI12807 · DOI · Paper page
  6. Hayakawa, 2000, Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines., Oncogene, 19, 624, 10.1038/sj.onc.1203354 · DOI · Paper page
  7. Guzman, 2001, Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells., Blood, 9, 2301, 10.1182/blood.V98.8.2301 · DOI · Paper page
  8. Min, 2003, Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable., Leukemia, 17, 995, 10.1038/sj.leu.2402874 · DOI · Paper page
  9. Xu, 2003, Survival of acute myeloid leukemia cells requires PI3 kinase activation., Blood, 102, 972, 10.1182/blood-2002-11-3429 · DOI · Paper page
  10. Birkenkamp, 2004, Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway., Leukemia, 18, 103, 10.1038/sj.leu.2403145 · DOI
  11. Grandage, 2005, PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways., Leukemia, 19, 586, 10.1038/sj.leu.2403653 · DOI · Paper page
  12. Sujobert, 2005, Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia., Blood, 106, 1063, 10.1182/blood-2004-08-3225 · DOI · Paper page
  13. Recher, 2005, mTOR, a new therapeutic target in acute myeloid leukemia., Cell Cycle, 4, 1540, 10.4161/cc.4.11.2159 · DOI
  14. Recher, 2005, Antileukemic activity of rapamycin in acute myeloid leukemia., Blood, 105, 2527, 10.1182/blood-2004-06-2494 · DOI · Paper page
  15. Bardet, 2006, Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry., Haematologica, 91, 757
  16. Quentmeier, 1997, The human bladder carcinoma cell line 5637 constitutively secretes functional cytokines., Leuk Res, 21, 343, 10.1016/S0145-2126(96)00132-4 · DOI
  17. Roginskaya, 1999, Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth., Leukemia, 13, 855, 10.1038/sj.leu.2401429 · DOI
  18. Jordan, 2000, The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells., Leukemia, 10, 1777, 10.1038/sj.leu.2401903 · DOI · Paper page
  19. Taussig, 2005, Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia., Blood, 106, 4086, 10.1182/blood-2005-03-1072 · DOI · Paper page
  20. Donella-Deana, 1998, Spontaneous autophosphorylation of Lyn tyrosine kinase at both its activation segment and C-terminal tail confers altered substrate specificity., Biochemistry, 37, 1438, 10.1021/bi971332s · doi:10.1021/bi971332s
  21. Robinson, 2005, Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations., Exp Hematol, 33, 469, 10.1016/j.exphem.2005.01.004 · DOI
  22. Contri, 2005, Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis., J Clin Invest, 115, 369, 10.1172/JCI200522094 · DOI · Paper page
  23. Brdicka, 2000, Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activation., J Exp Med, 191, 1591, 10.1084/jem.191.9.1591 · DOI · Paper page
  24. Ohtake, 2002, Transmembrane phosphoprotein Csk-binding protein/phosphoprotein associated with glycosphingolipid-enriched microdomains as a negative feedback regulator of mast cell signaling through the FcepsilonRI., J Immunol, 168, 2087, 10.4049/jimmunol.168.5.2087 · DOI
  25. Xu, 2005, Lyn tyrosine kinase: accentuating the positive and the negative., Immunity, 22, 9
  26. Tartaglia, 2004, Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia., Blood, 104, 307, 10.1182/blood-2003-11-3876 · DOI · Paper page
  27. Chen, 2005, FLT3/ITD mutation signaling includes suppression of SHP-1., J Biol Chem, 280, 5361, 10.1074/jbc.M411974200 · DOI
  28. Johan, 2005, Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia., Br J Haematol, 129, 60, 10.1111/j.1365-2141.2005.05412.x · DOI
  29. Watanabe, 2004, Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines., Br J Haematol, 126, 726, 10.1111/j.1365-2141.2004.05107.x · DOI
  30. Caligiuri, 2007, Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia., Blood, 110, 1022, 10.1182/blood-2006-12-061176 · DOI
  31. Sargin, 2007, Flt3-dependent transformation by inactivating c-Cbl mutations in AML., Blood, 110, 1004, 10.1182/blood-2007-01-066076 · DOI · Paper page
  32. Harder, 2001, Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage., Immunity, 15, 603, 10.1016/S1074-7613(01)00208-4 · DOI · Paper page
  33. Mermel, 2006, Src-family kinases are important negative regulators of G-CSF dependent granulopoiesis., Blood, 108, 2562, 10.1182/blood-2006-05-024307 · DOI
  34. Lannutti, 2006, Increased megakaryocytopoiesis in Lyn-deficient mice., Oncogene, 25, 3316, 10.1038/sj.onc.1209351 · DOI
  35. Karur, 2006, Lyn kinase promotes erythroblast expansion and late-stage development., Blood, 108, 1524, 10.1182/blood-2005-09-008243 · DOI
  36. Hu, 2004, Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia., Nat Genet, 36, 453, 10.1038/ng1343 · DOI · Paper page
  37. Ptasznik, 2004, Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells., Nat Med, 10, 1187, 10.1038/nm1127 · DOI · Paper page
  38. Okamoto, 2007, Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD., Leukemia, 21, 403, 10.1038/sj.leu.2404547 · DOI
  39. Martelli, 2006, Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia., Leukemia, 20, 911, 10.1038/sj.leu.2404245 · DOI · Paper page
  40. Zhu, 2006, G-CSF induced reactive oxygen species involves Lyn-PI3-kinase-Akt and contributes to myeloid cell growth., Blood, 107, 1847, 10.1182/blood-2005-04-1612 · DOI · Paper page
  41. Tamburini, 2006, Rationale for specific inhibition of both PI3K/AKT and mTORC1 activities in acute myelogenous leukaemia., Blood, 108, 1904, 10.1182/blood.V108.11.1904.1904 · doi:10.1182/blood.v108.11.1904.1904
  42. Billottet, 2006, A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16., Oncogene, 25, 6648, 10.1038/sj.onc.1209670 · DOI
  43. Leseux, 2006, Syk-dependent mTOR activation in follicular lymphoma cells., Blood, 108, 4156, 10.1182/blood-2006-05-026203 · DOI · Paper page

Cited by

See all 141

Metadata

Authors
Dos Santos, C., Demur, C., Bardet, V., Prade-Houdellier, N., Payrastre, B., & Récher, C.
Affiliations
  • Inserm U563, Centre de Physiopathologie de Toulouse Purpan, Département d'Oncogenèse, Signalisation et Innovation Thérapeutique, Université Toulouse III Paul Sabatier, IFR30, Toulouse;
  • Inserm U567, Centre National de la Recherche Scientifique (CNRS)–UMR 8104, Institut Cochin, Service d'Hématologie Biologique, Assistance Publique des Hâpitaux de Paris (AP-HP), Hôpital Cochin, Paris; and
Venue
Blood
Published
2008-02-15
Volume
111
Issue
4
Pages
2269-2279
ISSN
  • 0006-4971
  • 1528-0020
Cited by
141
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A critical role for Lyn in acute myeloid leukemia. https://app.cochat.ai/papers/10.1182/blood-2007-04-082099
The paper
Dos Santos, C., Demur, C., Bardet, V., Prade-Houdellier, N., Payrastre, B., & Récher, C. (2008). A critical role for Lyn in acute myeloid leukemia. Blood. https://doi.org/10.1182/blood-2007-04-082099

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.